Holen Sie sich die Stockscreener-App
40.00
0.88%
0.35
Handel nachbörslich:
40.00
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
What risks could impact Agios Pharmaceuticals Inc. stock performanceFree Stock Market Trend Analysis - jammulinksnews.com
Is Agios Pharmaceuticals Inc. a good long term investmentTremendous financial leverage - Autocar Professional
Will Agios Pharmaceuticals Inc. stock split in the near futureJaw-dropping returns - jammulinksnews.com
When the Price of (AGIO) Talks, People Listen - news.stocktradersdaily.com
What drives Agios Pharmaceuticals Inc. stock priceTriple-digit returns - Autocar Professional
BlackRock, Inc. Reduces Stake in Agios Pharmaceuticals Inc - GuruFocus
Agios Pharmaceuticals Inc. Stock Analysis and ForecastFree Smart Trading Workshop - jammulinksnews.com
What analysts say about Agios Pharmaceuticals Inc. stockFree Consultation - jammulinksnews.com
Lobbying Update: $20,000 of AGIOS PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Agios Pharmaceuticals (AGIO): Analyst Maintains Buy Rating, Lowe - GuruFocus
Agios Pharmaceuticals (AGIO): BofA Adjusts Price Target Amid Rev - GuruFocus
Agios Pharmaceuticals (AGIO) Moves 7.7% Higher: Will This Strength Last? - MSN
What makes Agios Pharmaceuticals Inc. stock attractive to long term investorsLow Risk Entry Points - Newser
Is Agios Pharmaceuticals Inc. stock a growth or value playFree Daily Stock Market Updates - Newser
Teacher Retirement System of Texas Lowers Stock Holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World
why agios pharmaceuticals inc. stock attracts strong analyst attentionSafe High Return Entry Points - Newser
What makes Agios Pharmaceuticals Inc. stock price move sharplyDaily Gain Forecast - Newser
Agios Pharmaceuticals to Host Conference Call on Second Quarter 2025 Financial Results and Business Highlights - Nasdaq
Rare Disease Leader Agios Sets Q2 Earnings Call: Key Updates Expected on PK Activation Therapies - Stock Titan
Public market insider buying at Extendicare (EXE) - The Globe and Mail
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Insider Sells $452,612.86 in Stock - Defense World
FY2025 Earnings Estimate for AGIO Issued By Zacks Research - Defense World
Trend Tracker for (AGIO) - news.stocktradersdaily.com
Agios pharma chief medical officer Gheuens sells $452,601 in stock By Investing.com - Investing.com Canada
Agios Pharmaceuticals Inc. (AGIO) Shares Soar 7.69% on FDA Designation - AInvest
Agios Pharma Appoints Dr. Jay Backstrom as Director - The Globe and Mail
Agios Pharmaceuticals appoints Jay Backstrom to board of directors By Investing.com - Investing.com South Africa
Agios Pharmaceuticals shares rise 3.64% intraday after appointing Dr. Jay Backstrom to its Board of Directors. - AInvest
Agios Appoints Dr. Jay Backstrom To Board - citybiz
Agios appoints Dr. Jay Backstrom to board of directors - MarketScreener
Agios Appoints Dr. Jay Backstrom to Board of Directors - The Manila Times
Agios Pharmaceuticals Appoints Dr. Jay Backstrom to Board of Directors - Quiver Quantitative
Agios Appoints Dr. Jay Backstrom to Board of Directors | AGIO St - GuruFocus
H.C. Wainwright Maintains a Buy Rating on Agios Pharmaceuticals (AGIO), Reduces PT - MSN
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Defensive Index - MarketScreener
Agios pharma chief legal officer Burns sells $93k in stock - Investing.com
Agios Pharmaceuticals, Inc. (AGIO) Backed by TD Cowen for Mitapivat’s Market Potential - MSN
Agios Pharma Increases Shares in Stock Incentive Plan - TipRanks
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):